An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.
In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.
Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.
A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.
An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.